Skip to main content
University of California San Francisco
About UCSF
Search UCSF
UCSF Medical Center
Radiology
Search
About
People
Opportunity and Outreach
Wellbeing and Professional Climate
Make a Gift
Contact Us
Patient Care
For Health Professionals
For Patients
Services Offered
Clinical Divisions
Patient Safety
Education
Diagnostic Radiology Residency
Integrated IR Residency
Independent IR Residency
NucMed Residency & Fellowship
Fellowships
T32 Program
Medical Student Education
Master of Science in Biomedical Imaging (MSBI)
Continuing Medical Education
The Margulis Society for Alumni
Distinguished Lecture Series
Research
Research Directory
Imaging Research Symposium
Research Conference
UCSF Radiology at RSNA
Core Services
Academic Affairs
Academic Recruitment
Academic Advancement
Development & Courses
Faculty Mentoring
Faculty Thrive Guide
Celebrating Faculty & Alumni
Department Committees
FAQs
Locations
News
Events
Honors and Awards
Department Publications
Breadcrumb
Home
/
About
/
People
/
Lisa Wilmes, PhD
/
Publications
Lisa Wilmes, PhD's Publications
MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer.
The QIBA Profile for Diffusion-Weighted MRI: Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker.
Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective Study.
Abstract P6-01-33: Diffusion-weighted magnetic resonance imaging for subtype-specific prediction of pathologic complete response in neoadjuvant chemotherapy.
Abstract PD16-07: Association of MRI morphologic phenotype from unsupervised learning with breast cancer subtypes and treatment response.
Chapter 14 Multiplatform Standardization of Breast DWI Protocols: Quality Control and Test Objects.
Abstract P3-03-02: Diffusion-weighted MRI for prediction of pathologic complete response in HER2- breast cancer treated with pembrolizumab plus neoadjuvant chemotherapy.
Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy.
Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer.
Long-Term Stability of Gradient Characteristics Warrants Model-Based Correction of Diffusion Weighting Bias.
Abstract PD6-05: Subtype-specific MRI models to guide selection of candidates for de-escalation of neoadjuvant therapy.
Abstract PS11-08: Operational standardization and quality assurance yield high acceptance rate for breast MRI in the I-SPY 2 TRIAL.
Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI.
Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial.
Denoising and Multiple Tissue Compartment Visualization of Multi-b-Valued Breast Diffusion MRI.
Denoising and Multiple Tissue Compartment Visualization of Multi-b-Valued Breast Diffusion MRI.
Factors Affecting Image Quality and Lesion Evaluability in Breast Diffusion-weighted MRI: Observations from the ECOG-ACRIN Cancer Research Group Multisite Trial (A6702).
Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial.
Mean Apparent Diffusion Coefficient Is a Sufficient Conventional Diffusion-weighted MRI Metric to Improve Breast MRI Diagnostic Performance: Results from the ECOG-ACRIN Cancer Research Group A6702 Diffusion Imaging Trial.
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.
Retrospective Correction of ADC for Gradient Nonlinearity Errors in Multicenter Breast DWI Trials: ACRIN6698 Multiplatform Feasibility Study.
Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer.
Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
Recommendations towards standards for quantitative MRI (qMRI) and outstanding needs.
Role of Breast MRI in the Evaluation and Detection of DCIS: Opportunities and Challenges.
Abstract P2-09-23: Diffusion-weighted MRI improves imaging prediction of response in the I-SPY 2 trial.
Abstract PD3-05: Effect of MR imaging contrast kinetic thresholds for prediction of neoadjuvant chemotherapy response in breast cancer subtypes – Results from ACRIN 6657 / I-SPY 1 trial.
Accuracy, repeatability, and interplatform reproducibility of T1 quantification methods used for DCE-MRI: Results from a multicenter phantom study.
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
Design of a breast phantom for quantitative MRI.
Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.
Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.
Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.
QIN DAWG Validation of Gradient Nonlinearity Bias Correction Workflow for Quantitative Diffusion-Weighted Imaging in Multicenter Trials.
Variability and bias assessment in breast ADC measurement across multiple systems.
Abstract C61: Non-homogeneous drug penetrance of veliparib measured in triple negative breast tumors.
Abstract P1-01-09: Optimization of magnetic resonance imaging predictive performance by breast cancer subtypes for predicting response to neoadjuvant chemotherapy.
Gradient nonlinearity correction to improve apparent diffusion coefficient accuracy and standardization in the american college of radiology imaging network 6698 breast cancer trial.
Repeatability of quantitative MRI measurements in normal breast tissue.
High resolution in vivo characterization of apparent diffusion coefficient at the tumor-stromal boundary of breast carcinomas: a pilot study to assess treatment response using proximity-dependent diffusion-weighted imaging.
High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response.
Diffusion-weighted MRI: influence of intravoxel fat signal and breast density on breast tumor conspicuity and apparent diffusion coefficient measurements.
High-resolution diffusion-weighted magnetic resonance imaging in patients with locally advanced breast cancer.
P2-08-06: Improved Spatial Resolution Diffusion-Weighted Imaging for Characterizing Tumors and Treatment Response in Patients with Invasive Breast Cancer.
P2-09-12: High Resolution Diffusion MRI Characterizes Tumor Stromal Boundaries.
Quantitative tissue oxygen measurement in multiple organs using 19F MRI in a rat model.
Magnetic resonance imaging for secondary assessment of breast density in a high-risk cohort.
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Characterization of breast lesions using the 3D FIESTA sequence and contrast-enhanced magnetic resonance imaging.
Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging.
Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development.
Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development.
Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
